Hernández CC, Núñez QA, Rodríguez FY, Carnot UJ, Chávez MR, Moya PI

Idioma: Español
Referencias bibliográficas: 37
Paginas: 197-204
Archivo PDF: 42.02 Kb.

RESUMEN

La leucemia mieloide aguda abarca un heterógeneo espectro de enfermedades, de naturaleza maligna y clonal, que representan un reto formidable para la medicina moderna. Con la excepción de la leucemia promielocítica, los resultados terapéuticos alcanzados continúan siendo desalentadores. Recientemente han surgido datos que demuestran mejores resultados con el uso de altas dosis de antraciclinas en la inducción. Se presentó el primer caso en Cuba, en cuya inducción se utilizó la rubidomicina a 100 mg/m2 por 3 d, más el arabinósido de citosina a 100 mg/m2 por 7 d, ambos en infusión endovenosa continua. La evolución clínica es satisfactoria hasta el momento. Se revisó brevemente la literatura médica al respecto.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program. 2009: 2009(1):396-405.

2. Lichtman MA, Liesveld JL. Leucemia mielógena aguda. En: Beutler E, Lichtman MA, Coller BS. Hematología, Williams. 6a ed. Madrid: Marbán Libros, S.L; 2005.p.1047-83.

3. Freireich EJ. Arabinosyl cytosine: a 20-year update. J Clin Oncol. 1987;5:523-4.

4. Coltman Jr CA, Freireich EJ, Pendleton O. Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials. Med Pediatr Oncol. 1982;10(Suppl. 1):173-83.

5. Weil M, Glidewell OJ, Jacquillat C. Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973;33:921-8.

6. Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Burnett MS, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453-74.

7. Hernández C. Leucemia mieloide aguda. Diagnóstico, estudio y tratamiento. En: Rodríguez H, Negrín JA. Manual de Prácticas Médicas. Hospital Clinicoquirúrgico "Hermanos Ameijeiras". 2da. ed. La Habana: Editorial Ciencias Médicas, 2008.

8. Hernández C, Pérez D, Carnot J, de Castro R, Muñío J, Martínez CA, et al. Tratamiento con quimioterapia de la leucemia mieloide aguda en el Hospital "Hermanos Ameijeiras." Experiencia de 20 años de trabajo. Rev Cubana Med. 2006;45(1).

9. Fernández HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Cur Op Hematol. 2010;17(2):79-84.

10. Rowe JM. Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)? Best Prac & Res Clin Haematol. 2009;22:509-15.

11. Rai KR, Holland JF, Glidewell OJ. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58:1203-12.

12. Preisler H, Davis RB, Kirshner J. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987;69:1441-9.

13. Vogler WR, Velez-Garcia E, Weiner RS. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992;10(7):1103-11.

14. Wiernik PH, Banks PLC, Case DC Jr. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2):313-9.

15. Berman E, Heller G, Santorsa J. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77(8):1666-74.

16. Mandelli F, Petti MC, Ardia A. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia: a multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer. 1991;27(6):750-5.

17. Hansen OP, Pedersen-Bjergaard J, Ellegaard J. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia.1991;5(6):510-6.

18. Berman E, Arlin ZA, Gaynor J. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia. 1989;3(2):115-21.

19. Arlin Z, Case DC Jr, Moore J. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia. 1990;4(3):177-83.

20. Weick JK, Kopecky KJ, Appelbaum FR. Arandomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8):2841-51.

21. Bishop JF, Matthews JP, Young GA. Randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87(5):1710-7.

22. Cassileth PA, Lee SJ, Litzow MR. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma. 2005;46(1):55-61.

23. Petersdorf SH, Rankin C, Head DR. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hematol. 2007;82(12):1056-62.

24. Bishop JF, Lowenthal RM, Joshua D. Etoposide in acute non lymphocytic leukemia. Blood. 1990;75(1):27-32.

25. Hann IM, Stevens RF, Goldstone AH. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood. 1997;89(7):2311-8.

26. Estey EH, Thall PF, Cortes JE. Comparison of idarubicin ara-C-, fludarabine araC-, and topotecan ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98(13):3575-83.

27. Ossenkoppele GJ, Graveland WJ, Sonneveld P. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 2004;103(8):2908-13.

28. Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107(12):4614-22.

29. List AF, Kopecky KJ, Willman CL. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98(12):3212-20.

30. Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(1):175-87.

31. Lowenberg B, van Putten W, Theobald M. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-52.

32. Thomas X, Raffoux E, de Botton S. Effect of priming with granulocyte-macrophage colonystimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453-61.

33. Buchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony stimulating factor-relationto high-dose cytarabine in acute myeloid leukemia. Engl J Med. 2004;350(21):2215-6.

34. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1301-3.

35. Kolitz JE, George SL, Dodge RK. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004;22:4290-301.

36. Pérez C, Agustí MA, Tornos P. Cardiotoxicidad tardía inducida por antraciclinas. Med Clin(Barc). 2009;133(8):311-3.

37. Lowenberg B, Ossenkoppele GJ, Van PW. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-48.